Galecto Inc.

01/27/2022 | Press release | Distributed by Public on 01/27/2022 06:10

Galecto Publishes Results Showing Safety and Efficacy of the GB0139 Inhaled Galectin-3 Inhibitor in Hospitalized COVID-19 Patients on Standard of Care